Codice QR

Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation

Treatment resistance and immune escape are hallmarks of metastatic rhabdomyosarcoma (RMS), underscoring the urgent medical need for therapeutic agents against this disease entity as a key challenge in pediatric oncology. Chimeric antigen receptor (CAR)-based immunotherapies, such as the ErbB2 (Her2)...

Descrizione completa

Salvato in:
Autori principali: Catrin Heim, Leonie Hartig, Nadine Weinelt, Laura M. Moser, Emilia Salzmann-Manrique, Michael Merker, Winfried S. Wels, Torsten Tonn, Peter Bader, Jan-Henning Klusmann, Sjoerd J.L. van Wijk, Eva Rettinger
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2024-06-01
Serie:Molecular Therapy: Oncology
Soggetti:
MT: Regular Issue
chimeric antigen receptor
immunotherapy
bortezomib
TRAIL
rhabdomyosarcoma
Accesso online:http://www.sciencedirect.com/science/article/pii/S2950329924000444
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi